The 6q23 chromosomal region harbors one of the strongest known genetic influences on autoimmune disease risk. Most people know of this locus through its risk variants — but rs13207033 tells the other side of the story. This intergenic SNP, located near the TNFAIP3 gene on chromosome 6, tags a protective haplotype¹¹ protective haplotype
A haplotype is a set of alleles inherited together on the same chromosome; rs13207033 marks a chromosomal block associated with higher TNFAIP3 activity that appears to enhance the activity of A20, the immune system's primary brake on NF-kB-driven inflammation. Carriers of the A allele show meaningfully reduced risk for rheumatoid arthritis, particularly in the autoantibody-positive form that causes the most destructive joint disease.

TNFAIP3 encodes A20, a ubiquitin-editing enzyme²² ubiquitin-editing enzyme
A20 uses two functional domains: a deubiquitinase that removes activating ubiquitin chains and an E3 ligase that adds inhibitory chains, together terminating NF-kB signal transduction that terminates NF-kB inflammatory signaling after an immune response has served its purpose. Without sufficient A20 activity, inflammatory signals persist and self-reactive immune responses become more likely — the fundamental mechanism underlying most autoimmune diseases.

The Mechanism

rs13207033 is located in the intergenic region near TNFAIP3 on chromosome 6q23.3, in a ~60-kb stretch between the OLIG3 and TNFAIP3 genes that does not encode any transcripts. It does not alter any protein directly; instead, it tags a regulatory haplotype³³ regulatory haplotype
A haplotype block in high linkage disequilibrium with rs13207033, meaning these alleles travel together across generations that appears to increase TNFAIP3 expression or enhance A20 function. The SNP is in perfect linkage disequilibrium⁴⁴ linkage disequilibrium
LD means the alleles co-occur more frequently than chance would predict, so rs13207033 and rs10499194 are essentially interchangeable markers for the same protective haplotype (r² = 1) with rs10499194, the variant more frequently tested in Asian-population studies. Carriers of the rs10499194 T allele (which perfectly tags the rs13207033 A allele) express higher levels of A20 mRNA, providing a plausible mechanism for the observed protective effect.

The consequence of enhanced A20 expression is more efficient termination of NF-kB signaling cascades. When the immune system encounters an antigen, NF-kB drives cytokine production and T-cell activation. A20 shuts this process down once the threat is cleared. Higher A20 expression means inflammatory responses resolve more completely, reducing the probability that immune activation becomes chronic and self-directed.

The Evidence

The protective nature of rs13207033 was established through conditional logistic regression⁵⁵ conditional logistic regression
A statistical method that identifies whether a variant remains independently significant after accounting for the effects of other nearby variants fine-mapping of the 6q23 locus. After accounting for the known risk variants rs6920220 and rs5029937, rs13207033 remained independently associated with RA protection (OR 0.86, 95% CI 0.80–0.93, P=0.0001) in 3,962 RA patients and 3,531 controls from six UK centers.

The protective effect is most pronounced in ACPA-positive RA⁶⁶ ACPA-positive RA
ACPA stands for anti-citrullinated protein antibodies — autoantibodies that mark the most aggressive, erosive form of rheumatoid arthritis; ACPA-positive RA has stronger genetic determinants than seronegative RA, where the A allele confers OR 0.80 (95% CI 0.66–0.96, P=0.015). This specificity makes biological sense: ACPA-positive RA is a more genetically driven, immune-mediated disease where A20 expression capacity directly constrains disease initiation and severity.

A meta-analysis of six studies⁷⁷ meta-analysis of six studies
Including 11,166 RA cases and 11,231 controls (11,166 cases / 11,231 controls) confirmed the protective association for GA vs GG genotype (OR 0.88, 95% CI 0.79–0.99, P=0.034) with the effect concentrated in Caucasian populations. No significant association was found in Asian or African-American populations, consistent with the lower A allele frequency in East Asian populations (~9.7% vs ~28% in Europeans).

Beyond RA, the rs13207033A–rs10499194T protective haplotype has been associated with reduced risk of ankylosing spondylitis⁸⁸ ankylosing spondylitis
A chronic inflammatory arthritis primarily of the spine and sacroiliac joints, classified as a spondyloarthropathy in Eastern Chinese Han populations (OR 0.60, 95% CI 0.42–0.87, P=0.006) — extending the protective signal beyond RA to other NF-kB-driven inflammatory arthritides.

The three-SNP model at 6q23 illustrates why individual variants tell only part of the story. The most dangerous haplotype combination — homozygous risk alleles at rs6920220 and rs5029937 with complete absence of the rs13207033 protective A allele — carries a combined OR of 1.86⁹⁹ combined OR of 1.86
95% CI 1.51–2.29, from formal three-SNP conditional analysis in 3,962 RA cases for RA, compared to OR 0.86 for the protective A allele alone.

Practical Implications

Carrying one or two copies of the A allele at rs13207033 is genetically favorable — it indicates greater capacity for NF-kB self-regulation via A20. For most A-allele carriers, this is a reassuring counterweight against other inflammatory risk factors. For homozygous GG carriers (lacking the protective allele entirely), the loss of this inherent protective signal is clinically meaningful primarily in the context of the companion 6q23 risk variants; as an isolated finding, GG genotype represents the common baseline population risk.

Two large-scale RCT interventions directly target the NF-kB pathway that A20 regulates. The VITAL trial¹⁰¹⁰ VITAL trial
A 5-year randomized controlled trial of 25,871 adults assigned to vitamin D3 2000 IU/day, omega-3 1 g/day, both, or placebo found vitamin D3 supplementation reduced incident autoimmune disease by 22% (HR 0.78, P=0.05) and omega-3 fatty acids reduced it by 15%. For GG carriers who lack the protective allele, these interventions represent the most evidence-backed approach to compensating for reduced genetic NF-kB braking capacity.

Interactions

rs13207033 is one of three statistically independent signals at the 6q23 locus. The other two — rs6920220 (intergenic, reduces TNFAIP3 transcription) and rs5029937 (intronic in TNFAIP3, also risk) — are independently inherited and their combination with rs13207033 genotype substantially alters overall RA risk. Carrying both risk alleles for the other two SNPs while being GG at rs13207033 (i.e., lacking the protective A allele) yields OR 1.86, the highest risk configuration at this locus.

The TNFAIP3 missense variant rs2230926 (F127C) operates through a different mechanism — impaired A20 enzymatic activity rather than altered expression — and is independent of the 6q23 haplotype block. Carriers of both the rs2230926 G risk allele and rs13207033 GG genotype lack both the quantitative (expression-level) and qualitative (enzyme-activity) components of A20 function, a combination that warrants a dedicated compound action assessment.

CD36 (also called fatty acid translocase, or FAT) is one of the body's key gatekeepers for dietary fat. It sits on the surface of cells throughout the intestine, tongue taste buds, platelets, macrophages, muscle, and adipose tissue. Its job is to bind long-chain fatty acids — the molecules that make up most of the fat in food — and shuttle them into cells. When CD36 expression is higher, cells take up more fat; when it is lower, fat stays in the bloodstream longer. rs13236689 is an intronic variant¹¹ intronic variant
A variant within a non-coding intron of the CD36 gene; these often act as expression regulators by altering transcription factor binding sites in the surrounding DNA that modulates how much CD36 protein cells produce.

The Mechanism

rs13236689 does not change the CD36 protein sequence — it lies within an intron on chromosome 7 at position 80,606,698 (GRCh38). Its biological significance lies in its status as a platelet expression quantitative trait locus (eQTL)²² platelet expression quantitative trait locus (eQTL)
An eQTL is a genomic variant that explains variation in how much of a gene's mRNA — and ultimately protein — is produced in a given tissue. Carriers of the G allele are in strong linkage disequilibrium with the functional regulatory variants rs2366739 and rs1194196, which sit approximately 13–55 kb upstream of the CD36 transcriptional start site and alter transcription factor binding. When these regulatory variants are active, platelet CD36 mRNA and surface protein levels increase. Higher platelet CD36 means stronger responses to oxidized LDL (oxLDL) — the chemically modified form of cholesterol that accumulates in atherosclerotic plaques — and greater platelet activation in lipid-rich environments.

The metabolic consequences extend beyond platelets. In the gut, enterocyte CD36 expression levels determine how efficiently long-chain fatty acids trigger satiety signals: CD36 converts dietary fatty acids into oleoylethanolamide (OEA)³³ oleoylethanolamide (OEA)
A bioactive lipid that activates PPARα in the gut wall, sending a sustained satiety signal to the brain via the vagus nerve, which in turn activates PPARα to prolong the feeling of fullness after a fat-rich meal. Variants that push CD36 expression higher also increase uptake of oxLDL by macrophages in artery walls — a key step in foam cell formation and atherosclerosis.

The Evidence

The primary genetic evidence for rs13236689 comes from the COGENT consortium meta-analysis⁴⁴ COGENT consortium meta-analysis
Cheng et al. (2012), PLoS Genetics — a meta-analysis of 7 genome-wide association studies in over 16,000 African Americans from population-based cohorts, which identified rs13236689 as a genome-wide significant locus for platelet count (p = 2.84×10⁻⁹; β = +4.18 × 10⁹ platelets/L per G allele). The association nominally replicated in European Americans. The same variant was subsequently shown by Madan et al. (2019, PLoS Genetics)⁵⁵ Madan et al. (2019, PLoS Genetics)
Using a massively parallel reporter assay to screen 81 CD36 eQTLs, the authors confirmed that rs13236689 is a bona fide eQTL for platelet CD36 mRNA, with the causal signal mapping to two nearby regulatory variants (rs2366739, rs1194196) in high LD to be a platelet CD36 eQTL: G allele carriers have higher platelet CD36 surface expression.

The downstream cardiovascular significance of CD36 expression variation is well-established: higher platelet CD36 augments oxLDL-induced platelet activation and has been associated with thromboembolism risk. At the gene level, Love-Gregory et al. (2008)⁶⁶ Love-Gregory et al. (2008)
Population study of 2,020 African Americans from the HyperGEN cohort; PMID 18305138 showed that multiple CD36 variants modulate HDL-C, triglycerides, and metabolic syndrome risk. The CD36 AGGIG haplotype in Caucasians was associated with 31% higher free fatty acids and OR 2.3 for cardiovascular events in type 2 diabetics (Corpeleijn et al. 2006, PMID 15282206)⁷⁷ (Corpeleijn et al. 2006, PMID 15282206).

Evidence for rs13236689's direct effect on dietary fat handling and plasma lipids is moderate — the lipid associations are inferred from the eQTL relationship and the well-established biology of CD36 expression, rather than from dedicated dietary intervention trials targeting this specific variant.

Practical Actions

Because rs13236689 G allele carriers have higher platelet CD36 expression, they are likely to mount stronger platelet responses to circulating oxidized LDL. This is most relevant in the context of a diet high in saturated and trans fats, which drive oxLDL production. Limiting foods that generate oxLDL — principally processed and ultra-processed foods containing oxidized vegetable oils and trans fats — is directly relevant to this genotype. Longer-chain omega-3 fatty acids (EPA/DHA) compete with pro-inflammatory fatty acids at the CD36 binding site and have been shown to reduce platelet activation. Monitoring fasting triglycerides and HDL-C provides a practical window into CD36-mediated fat metabolism; the CD36 eQTL mechanism links directly to postprandial lipemia.

Interactions

rs13236689 is in linkage disequilibrium with other CD36 expression-regulating variants. The most studied CD36 SNP, rs1761667 (promoter, −31118G>A), directly affects fat taste sensitivity — AA homozygotes have 8-fold higher detection thresholds for oleic acid, meaning they perceive fat less intensely and tend to eat more of it. If a person carries both rs13236689 G (higher CD36 in platelets/ macrophages) and rs1761667 AA (lower fat taste sensitivity from reduced tongue CD36), the combined effect — increased cardiovascular risk from platelet hyperactivation alongside blunted dietary fat sensing — warrants attention. rs3211938 is a CD36 truncation variant (stop-gain) that dramatically reduces CD36 protein; this variant is functionally distinct from rs13236689 and largely confined to African-ancestry populations.

When a macrophage migrates into a lipid-laden arterial wall and begins absorbing oxidized cholesterol, it faces a critical choice: offload that cargo to HDL particles and survive, or become overwhelmed by cholesterol accumulation and transform into a foam cell. This offloading depends heavily on the ABCG1 transporter¹¹ ABCG1 transporter
ATP-binding cassette subfamily G member 1, a membrane pump that mediates cholesterol and phospholipid efflux from macrophages to mature HDL particles — the rate-limiting step in macrophage reverse cholesterol transport. When macrophage ABCG1 function is compromised, cholesterol accumulates, foam cells form, and the necrotic core of atherosclerotic plaques expands — a process that is directly linked to plaque instability and rupture, the proximate cause of most atherothrombotic strokes.

The rs1378577 variant sits approximately 2 kilobases upstream of the ABCG1 transcription start site on chromosome 21. Located in a regulatory region that influences ABCG1 expression, this T>G substitution is part of the promoter-region haplotype that has been studied in relation to ischemic stroke in Asian populations. The G allele at rs1378577 appears to be associated with reduced stroke risk — particularly the atherothrombotic subtype, which is characterized by large-artery atherosclerosis and plaque-related events.

The Mechanism

As an upstream regulatory variant, rs1378577 likely influences the binding of transcriptional regulators to the ABCG1 locus, modulating expression levels rather than altering the protein sequence directly. The ABCG1 gene on chromosome 21 is expressed widely, with particularly important roles in macrophages and monocytes that reside within arterial walls.

ABCG1 facilitates the transfer of cholesterol from macrophage plasma membranes to mature, spherical HDL particles²² ABCG1 facilitates the transfer of cholesterol from macrophage plasma membranes to mature, spherical HDL particles
this step follows ABCA1-mediated lipidation of apolipoprotein A-I into nascent HDL; the two transporters work sequentially — ABCA1 initiates the HDL particle, ABCG1 enlarges it. Reduced ABCG1 expression impairs this efflux step, leaving macrophages with excess intracellular cholesterol that promotes foam cell differentiation. ABCG1 deficiency also amplifies Toll-like receptor (TLR4) signaling in macrophages, heightening inflammatory cytokine release — a mechanism that independently accelerates plaque vulnerability independent of cholesterol level effects.

Variants in the ABCG1 promoter region that reduce transcriptional activity could therefore impair reverse cholesterol transport at the arterial wall specifically, contributing to plaque growth and instability. The nearby promoter variant rs57137919 has been confirmed by luciferase assay to alter ABCG1 promoter activity; rs1378577 is part of the same upstream regulatory haplotype and is in linkage disequilibrium with the promoter region variants studied in Chinese Han populations.

The Evidence

The primary study of rs1378577 is Li et al. 2015 (Journal of Stroke and Cerebrovascular Diseases)³³ Li et al. 2015 (Journal of Stroke and Cerebrovascular Diseases), a case-control study of 389 ischemic stroke patients and 380 healthy controls in a Chinese Han population. In the overall cohort, no significant association was detected — but when stroke was subtyped, the G allele and TG+GG genotypes of rs1378577 were specifically associated with reduced risk of atherothrombotic stroke, the subtype driven by large-artery plaque rupture rather than cardioembolic or lacunar mechanisms. The association was particularly pronounced in the hypertriglyceridemic subgroup (144 cases, 115 controls), where the GG genotype was markedly less frequent among stroke patients, suggesting the G allele's protection is most evident when metabolic stress on macrophage lipid handling is highest.

Yang et al. 2022 (Gene)⁴⁴ Yang et al. 2022 (Gene) studied 10 ABCA1/G1 SNPs in 249 ischemic stroke patients and 226 controls, confirming that ABCG1 variants are associated with plasma lipid differences and stroke susceptibility in this population. The studies are consistent in pointing to ABCG1's role in HDL-mediated cholesterol transport as the biological substrate linking genotype to stroke risk.

Wang et al. 2020 (Annals of Vascular Surgery)⁵⁵ Wang et al. 2020 (Annals of Vascular Surgery) provided functional context by showing that ABCG1 promoter polymorphisms are associated with plasma HDL-C and LDL-C differences in Chinese Han individuals, consistent with the transporter's known role in systemic lipoprotein metabolism.

Important limitation: all published studies are from Chinese Han populations. Effect size estimates may differ in European, African, or South Asian ancestry groups. The G allele is notably more common in African populations (~50%) than European (~23%), which may reflect population-specific selection pressures and could affect how absolute risk differences translate across ancestries. Mechanistic evidence for ABCG1's role in macrophage cholesterol efflux and atherosclerosis is well-established across populations; the variant-level association requires replication in non-Asian cohorts.

Evidence level is moderate: replicated in multiple Chinese Han studies with a biologically plausible mechanism, but replication in diverse non-Asian populations is incomplete, and exact odds ratios from the abstract-available data are limited.

Practical Actions

For individuals carrying the T/T genotype (most common, ~58% globally): HDL-mediated cholesterol clearance from macrophages operates at baseline levels without the G-allele influence. Supporting ABCG1-dependent reverse cholesterol transport through specific dietary strategies — particularly increasing HDL particle function and reducing LDL oxidation exposure at arterial walls — is the most directly relevant action for this genotype.

For G/T heterozygotes: partial G-allele benefit may improve macrophage cholesterol efflux capacity and lipid profiles to an intermediate degree. Monitoring lipids and tracking HDL-C trends confirms whether the expected benefit is expressed.

For GG homozygotes: the G allele's protective association with atherothrombotic stroke is most pronounced in this genotype. This is particularly relevant in the context of elevated triglycerides, where ABCG1-dependent efflux faces the greatest metabolic challenge.

Interactions

rs1378577 is part of the same genomic region as rs57137919, an ABCG1 promoter variant associated with HDL-C, LDL-C, and CAD/stroke risk. Both variants are in linkage disequilibrium in Chinese Han populations, and their effects on ABCG1 expression are likely partially overlapping. Users carrying G alleles at both loci may experience compounded ABCG1 expression effects in macrophages.

ABCG1 works sequentially with ABCA1 in macrophage cholesterol efflux — ABCA1 (rs4149338) creates nascent HDL particles, ABCG1 (rs1378577) then loads cholesterol onto those particles. The Li et al. 2015 study examined both genes: ABCA1 variants showed opposing risk directions compared to ABCG1 variants, highlighting that dysfunction at either step in the efflux cascade can impair reverse cholesterol transport. The two-gene combination is a candidate for compound interaction analysis.

HMGA1 (High Mobility Group AT-Hook 1) encodes a non-histone chromosomal protein that functions as a transcriptional regulator¹¹ transcriptional regulator
HMGA1 binds to A/T-rich regions of DNA and remodels chromatin structure, enabling other transcription factors to access their target genes. It acts as an architectural transcription factor — rather than directly activating genes, it reshapes the DNA landscape to allow or prevent other regulators from doing their work. The rs1776897 variant sits in an intergenic region near HMGA1 on chromosome 6 and influences where your body preferentially stores fat.

The Mechanism

HMGA1 plays a documented role in insulin signaling and glucose metabolism. Mouse studies²² Mouse studies
HMGA1-deficient mice develop obesity, glucose intolerance, and insulin resistance, demonstrating a causal role for this gene in metabolic regulation have shown that HMGA1 deficiency leads to obesity, glucose intolerance, and insulin resistance. The protein regulates the expression of the insulin receptor itself, and reduced HMGA1 function leads to decreased insulin receptor expression on cell surfaces.

The rs1776897 G allele is associated with altered HMGA1 regulatory activity in adipose tissue, promoting central (abdominal) fat deposition rather than peripheral storage. This variant shows marked sexual dimorphism³³ sexual dimorphism
The effect on WHR is substantially stronger in women than in men, a pattern shared by many fat distribution loci, with stronger effects in women.

The Evidence

The Shungin et al. 2015 meta-analysis⁴⁴ Shungin et al. 2015 meta-analysis
Shungin et al. New genetic loci link adipose and insulin biology to body fat distribution. Nature, 2015 identified the HMGA1 locus among 49 genome-wide significant loci for waist-to-hip ratio adjusted for BMI (WHRadjBMI) across 224,459 individuals. HMGA1 was specifically highlighted as one of the transcriptional regulators at WHRadjBMI loci, and the signal showed stronger effects in women.

A Mendelian randomization study⁵⁵ Mendelian randomization study
Emdin et al. Genetic association of waist-to-hip ratio with cardiometabolic traits, type 2 diabetes, and coronary heart disease. JAMA, 2017 demonstrated that WHR-raising variants, including the HMGA1 locus, are causally linked to increased risk of type 2 diabetes (OR 1.77 per 1-SD increase in WHR) and coronary heart disease (OR 1.46). This moves the evidence beyond mere association — the fat distribution pattern itself drives metabolic disease.

The largest body fat distribution GWAS to date⁶⁶ largest body fat distribution GWAS to date
Pulit et al. Meta-analysis of genome-wide association studies for body fat distribution in 694,649 individuals of European ancestry. Hum Mol Genet, 2019 confirmed the HMGA1 locus among replicated fat distribution signals across nearly 700,000 individuals.

Practical Actions

The HMGA1 variant's effect on central fat deposition means that waist-to-hip ratio is a more meaningful health metric than BMI or total weight for carriers of the G allele. Central adiposity, even without overall obesity, carries metabolic risk. Monitoring insulin sensitivity markers and focusing on reducing visceral fat specifically are appropriate responses.

Interactions

HMGA1 sits within a broader network of fat distribution loci. The Shungin et al. 2015 pathway analysis implicated adipogenesis, angiogenesis, transcriptional regulation, and insulin resistance as interconnected processes. Carriers of WHR-raising alleles at multiple loci (including TFAP2B rs987237 and VEGFA rs6905288) may have compounded central adiposity risk, though formal gene-gene interaction studies are limited for these specific combinations.

BRCA1 is perhaps the most recognized cancer-associated gene in public awareness, largely because rare, high-penetrance pathogenic mutations¹¹ pathogenic mutations
Frameshift, nonsense, and splice-site mutations that severely disrupt or abolish BRCA1 protein function, carrying lifetime breast cancer risks of 60-80% in BRCA1 confer lifetime breast cancer risks of 60-80%. The rs1799950 variant (Q356R) is fundamentally different: it is a common missense polymorphism found in roughly 5% of European chromosomes that does not abolish BRCA1 function and is not classified as a pathogenic mutation. Understanding this distinction is essential — carrying Q356R does not place you in the clinical category of "BRCA1 mutation carriers" and does not qualify for the intensive screening and risk-reduction protocols applied to pathogenic BRCA1 mutation carriers.

The Mechanism

The Q356R substitution replaces glutamine (a polar, uncharged amino acid) with arginine (a positively charged amino acid) at position 356 of the BRCA1 protein. This position lies near — but not within — the RING finger domain²² RING finger domain
A zinc-binding structural motif (residues 1-109) essential for BRCA1's E3 ubiquitin ligase activity; the RING domain mediates the BRCA1-BARD1 interaction critical for DNA repair signaling (residues 1-109) that mediates the critical BRCA1-BARD1 protein interaction required for E3 ubiquitin ligase activity³³ E3 ubiquitin ligase activity
An enzymatic function where BRCA1-BARD1 attaches ubiquitin tags to target proteins, marking them for degradation or signaling DNA repair pathways to activate.

Population frequency comparisons have shown that the arginine substitution at position 356 is present at similar rates⁴⁴ is present at similar rates
Durocher F et al. Comparison of BRCA1 polymorphisms, rare sequence variants and/or missense mutations in unaffected and breast/ovarian cancer populations. Hum Mol Genet, 1996 in cancer-affected and unaffected populations, indicating no strong pathogenic effect. The protein retains its core DNA repair functions — homologous recombination, checkpoint activation, and chromatin remodeling. This is consistent with the variant's classification as benign/likely benign by ClinVar⁵⁵ ClinVar
The NIH database of clinically relevant genomic variants and their relationship to human health and the ENIGMA consortium⁶⁶ ENIGMA consortium
Parsons MT et al. Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification. Hum Mutat, 2019.

The Evidence

Durocher et al.⁷⁷ Durocher et al.
Durocher F et al. Comparison of BRCA1 polymorphisms, rare sequence variants and/or missense mutations in unaffected and breast/ovarian cancer populations. Hum Mol Genet, 1996 evaluated Q356R in the earliest systematic BRCA1 polymorphism comparison, finding no statistically significant difference in allele frequency between breast/ovarian cancer cases and controls. Subsequent prospective and case-control analyses have reported similarly null or borderline findings.

A large prospective and case-control study by Dombernowsky et al.⁸⁸ Dombernowsky et al.
Dombernowsky SL et al. Missense polymorphisms in BRCA1 and BRCA2 and risk of breast and ovarian cancer. Cancer Epidemiol Biomarkers Prev, 2009 specifically examined Q356R alongside eight other BRCA1/2 missense polymorphisms and found no association with breast or ovarian cancer risk. The variant's effect, if any, is in the range seen with many common, low-penetrance susceptibility alleles⁹⁹ susceptibility alleles
Common genetic variants that individually confer very small increases in disease risk (typically OR < 1.3), in contrast to rare, high-penetrance mutations with OR > 5 identified through GWAS — individually modest, collectively relevant only in the context of polygenic risk models.

The ENIGMA consortium multifactorial analysis¹⁰¹⁰ ENIGMA consortium multifactorial analysis
Parsons MT et al. Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification. Hum Mutat, 2019 applied multifactorial likelihood methods incorporating clinical, segregation, functional, and population data to classify BRCA1/2 variants. The conclusion: benign/likely benign for common missense polymorphisms like Q356R. The variant does not segregate with disease in high-risk families, is too common in unaffected populations to be pathogenic, and population frequency data do not support pathogenicity.

Practical Implications

The critical message for Q356R carriers is what this variant is not. It is not a pathogenic BRCA1 mutation. It does not warrant prophylactic surgery, intensive MRI screening, or the risk-reduction protocols designed for true BRCA1/2 mutation carriers. The absolute risk increase, if any, is small — on the order of a few percentage points over a lifetime.

That said, even modest genetic risk signals have value when they prompt awareness and inform screening decisions proportionate to the actual risk level. For women carrying one or two copies of the C allele, the appropriate response is adherence to recommended breast cancer screening for their age and family history context — not the intensive surveillance reserved for high-penetrance BRCA1 mutations.

Awareness of antioxidant support for DNA repair pathways is reasonable, given that Q356R subtly affects a protein at the center of homologous recombination repair. Nutrients that support BRCA1-mediated DNA repair — particularly folate (for nucleotide synthesis during repair) and selenium (which supports p53 and other tumor suppressors that cooperate with BRCA1) — are relevant but do not require aggressive supplementation.

Interactions

BRCA1 Q356R (rs1799950) and BRCA1 E1038G (rs16941) are both common missense variants in the same gene, and their potential compound effect is of interest. Rs16941 (E1038G) lies in the BRCT domain region and is considerably more common (C allele frequency ~30% in Europeans). Individually, both variants are classified as benign/likely benign with modest-at-best risk associations. However, individuals carrying risk alleles at both loci have two distinct BRCA1 missense changes simultaneously — one near the RING domain (Q356R) and one in the BRCT domain region (E1038G). The combined effect on BRCA1 protein function has not been rigorously quantified in published literature, but the possibility of additive subtle impairment across two functional regions of the same protein is biologically plausible. If a user carries the C allele at both rs1799950 and rs16941, the aggregate signal from two BRCA1 missense variants — while still far below the threshold for pathogenic BRCA1 carrier management — may warrant heightened awareness of breast cancer screening adherence.

Additionally, rs11571833 (BRCA2 K3326X) is a related stop-gain variant in BRCA2. While in a different gene, both BRCA1 and BRCA2 operate in the homologous recombination DNA repair pathway. Carriers of risk alleles at both rs1799950 (BRCA1) and rs11571833 (BRCA2) have variants in both major HR repair genes, which could theoretically compound DNA repair efficiency reduction.

MLH1 (mutL homolog 1) is a cornerstone of the DNA mismatch repair (MMR) system¹¹ DNA mismatch repair (MMR) system
A proofreading pathway that detects and corrects replication errors — particularly base mismatches and small insertions/deletions — before they become heritable mutations, the cellular proofreading machinery that catches errors after DNA replication. MLH1 heterodimerizes with PMS2 to form MutLα, which acts as the "decision-maker" complex that couples mismatch recognition (by MutSα/MutSβ) with excision and repair. Loss of MLH1 function is the defining molecular event in Lynch syndrome — the most common hereditary colorectal cancer syndrome — and in a subset of sporadic microsatellite-unstable cancers. MLH1 also plays a distinct, essential role in meiotic recombination²² meiotic recombination
The controlled exchange of DNA between paired homologous chromosomes during egg and sperm formation; MLH1 marks and stabilizes the sites where chromosomes will cross over, where MLH1-MLH3 marks the sites where homologous chromosomes will exchange DNA during formation of eggs and sperm.

The Ile219Val variant (c.655A>G, p.Ile219Val) substitutes valine for isoleucine at position 219 — a conserved buried hydrophobic residue within the N-terminal ATPase domain. It is the most frequent exonic polymorphism in MLH1³³ most frequent exonic polymorphism in MLH1
Tournier et al. 2004, Hum Mutat — identified as the most common MLH1 coding variant across European cohorts, present in roughly one in three Europeans. Despite its location in a functionally critical domain, multiple lines of evidence classify it as benign with respect to mismatch repair capacity.

The Mechanism

Position 219 sits within the N-terminal ATPase domain of MLH1⁴⁴ N-terminal ATPase domain of MLH1
Residues 1–347 constitute the ATPase "GHKL" domain, which binds and hydrolyzes ATP to drive conformational changes required for mismatch repair and coordination of downstream repair factors. Isoleucine and valine are both nonpolar, aliphatic residues with similar side-chain volumes — valine is simply two methylene groups shorter. This conservative substitution at a buried hydrophobic position makes structural disruption unlikely.

Plotz et al.⁵⁵ Plotz et al.
Plotz G et al. Evaluation of the MLH1 I219V alteration in DNA mismatch repair activity and ulcerative colitis. Int J Colorectal Dis, 2008 performed in silico structural analysis and quantitative biochemical assays and found "identical stability and activity of the protein" compared to wild-type MLH1. The variant was described as "unlikely to abolish MLH1 function but may modulate it" — a subtle distinction that has guided subsequent functional research. The same conclusion was reached independently by Vogelsang et al.⁶⁶ Vogelsang et al.
Vogelsang M et al. Assessing pathogenicity of MLH1 variants by co-expression of human MLH1 and PMS2 genes in yeast. Int J Cancer, 2009, who classified I219V as non-pathogenic in a yeast co-expression assay with human PMS2.

The word "modulate" in the Plotz conclusion — not "abolish" — leaves open the possibility that the Val allele introduces subtle kinetic differences in ATPase cycling. The ATPase activity of MLH1 drives the conformational changes that open and close the MutLα clamp during mismatch repair. If Val219 alters ATP hydrolysis rates marginally without impairing repair altogether, this could manifest as altered repair efficiency under high mutation burden — a context relevant to chemotherapy response and rapidly proliferating cells.

In meiosis, MLH1 marks approximately 90% of obligate crossover sites⁷⁷ 90% of obligate crossover sites
MLH1 foci on meiotic chromosomes visualized by immunofluorescence correspond to crossover events that ensure proper chromosome segregation; each chromosome pair needs at least one crossover to segregate correctly on meiotic chromosomes. Whether subtle Val219 modulation of ATPase activity affects crossover placement or efficiency has not been directly studied.

The Evidence

For Lynch syndrome: the InSiGHT expert panel has reviewed this variant and classified it as Benign⁸⁸ classified it as Benign
ClinVar VCV000036557, reviewed by InSiGHT 2013; 30+ consistent submitters all classifying as benign or likely benign; high population frequency cited as key evidence based on high population frequency, functional data, and presence in unaffected individuals. Chen et al.⁹⁹ Chen et al.
Chen H et al. Association between MutL homolog 1 polymorphisms and the risk of colorectal cancer: a meta-analysis. J Cancer Res Clin Oncol, 2015 confirmed this in a meta-analysis of 29,114 individuals: rs1799977 showed no association with colorectal cancer risk in any of four genetic models tested.

The picture is more nuanced in other cancer contexts. A meta-analysis of breast cancer¹⁰¹⁰ meta-analysis of breast cancer
Zhang Q et al. Association of Polymorphisms of Mismatch Repair Genes hMLH1 and hMSH2 with Breast Cancer Susceptibility. Crit Rev Eukaryot Gene Expr, 2020 (9 hMLH1 studies) found that the G allele (GA+GG genotype) was associated with increased breast cancer susceptibility, particularly in Caucasian women. Mechanistically, this could reflect subtle repair modulation under high replication stress in rapidly dividing breast epithelium — a different context from the colon.

Most striking is the DLBCL survival data: Rossi et al.¹¹¹¹ Rossi et al.
Rossi D et al. The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphoma. Blood, 2011 found that MLH1 rs1799977 AG/GG genotype independently predicted overall survival in DLBCL (HR=3.23, P<0.001) and predicted inferior response to R-CHOP21 (HR=2.02) and platinum-based therapy (HR=2.26). This likely reflects the role of intact MLH1 in processing alkylating agent and platinum-induced DNA damage¹²¹² alkylating agent and platinum-induced DNA damage
Chemotherapy agents like doxorubicin and cisplatin create DNA damage that stalls replication; cells with efficient MMR recognize and respond to this damage differently than MMR-impaired cells — the very "modulation" Plotz described may amplify under chemotherapy-level DNA damage load.

Campbell et al.¹³¹³ Campbell et al.
Campbell PT et al. Mismatch repair polymorphisms and risk of colon cancer, tumour microsatellite instability and interactions with lifestyle factors. Gut, 2009 (n=1,609 cases, 1,972 controls) found no independent colon cancer association but identified a statistically significant interaction between the Ile219Val genotype and Western diet consumption (p=0.03) — suggesting the variant's functional modulation may emerge specifically under dietary conditions that increase DNA damage or alter repair demands.

Practical Implications

This variant does not cause Lynch syndrome and does not require Lynch syndrome surveillance protocols. For the great majority of carriers, it is a benign common polymorphism. The actionable considerations are:

For cancer screening: Standard colorectal cancer screening at age 45 applies — this variant does not change that schedule. The potential breast cancer signal is modest and population-based, not individually predictive.

For chemotherapy-treated patients: The DLBCL survival data is the most clinically significant finding. Carriers receiving DNA-damaging chemotherapy may have altered treatment responses — oncologists treating AG/GG carriers for DLBCL or other chemosensitive cancers should be aware of this pharmacogenomic context.

For gamete quality: MLH1's meiotic crossover function means that any modulation of ATPase activity could theoretically affect crossover placement or number. Direct evidence for fertility effects of this specific variant is lacking, but in the context of assisted reproduction (IVF/ICSI), awareness of MLH1 variant status is emerging as potentially relevant to gamete quality assessment.

Interactions

EXO1 rs72755295: EXO1 (exonuclease 1) is the primary resection enzyme in MLH1-directed mismatch excision, and also cooperates with MLH1-MLH3 in meiotic crossover resolution. Approximately 80% of meiotic crossovers require both MLH1-MLH3 endonuclease activity and EXO1 function. The EXO1 rs72755295 G allele increases EXO1 expression and is associated with earlier menopause. A carrier of both the MLH1 Ile219Val G allele (potentially modulating ATPase kinetics) and the EXO1 rs72755295 G allele (increasing excision capacity) could have an imbalanced MLH1-EXO1 stoichiometry in meiotic cells. No published study has directly assessed this combination.

MLH1 rs1800734 (-93G>A): The promoter variant in the same gene. rs1800734 reduces MLH1 expression; rs1799977 modulates protein function. A carrier of both the promoter A allele (reduced expression) and the coding G allele (Val219) would have both quantitatively less and functionally subtly different MLH1 — a compound state that no single-variant analysis captures. The Plotz and Vogelsang functional studies assessed I219V in isolation; combined effects have not been studied.

DLBCL chemotherapy context: The strong survival signal in DLBCL (Rossi et al.) suggests that under high-intensity DNA damage (R-CHOP21, platinum compounds), the I219V modulation becomes clinically significant. This interaction with chemotherapy is arguably the highest- evidence actionable finding from this variant.

The CYP2R1 gene¹¹ CYP2R1 gene
Cytochrome P450 family 2 subfamily R member 1; encodes the primary liver enzyme responsible for converting vitamin D3 (cholecalciferol) into 25-hydroxyvitamin D, the storage and transport form measured in blood tests is the gatekeeper of vitamin D activation. Before vitamin D can do anything useful in the body, the liver must convert it from its ingested or sun-derived form into 25-hydroxyvitamin D (25(OH)D)²² 25-hydroxyvitamin D (25(OH)D)
Also called calcidiol; this is the form measured in standard blood tests and the main circulating vitamin D metabolite. The kidneys then convert it further into calcitriol, the active hormone. CYP2R1 performs this critical first hydroxylation step. rs1993116 is an intronic variant that influences how efficiently CYP2R1 is expressed — people carrying the G allele produce less of this enzyme, leaving more vitamin D unconverted.

The Mechanism

rs1993116 sits within an intron of CYP2R1 on chromosome 11 (GRCh38: chr11:14,888,688). Because CYP2R1 is on the minus strand, the variant is described using plus-strand alleles in genome files: A (the minor, protective allele) versus G (the major, risk allele). The intronic position suggests the variant affects splicing efficiency or enhancer activity³³ splicing efficiency or enhancer activity
Intronic variants can alter the binding of splicing regulatory proteins or transcription factors, changing the amount of functional mRNA produced without changing the protein sequence itself rather than the enzyme's catalytic activity directly. The net effect is that G allele carriers produce less CYP2R1 protein and therefore convert less dietary and sun-derived vitamin D into its measurable 25(OH)D form.

This variant is in partial linkage disequilibrium with rs10741657, the more commonly cited CYP2R1 GWAS locus, but the two variants are not perfectly correlated — each captures some independent variation in CYP2R1 expression. In European Americans, rs1993116 has been reported as the most strongly associated CYP2R1 variant with 25(OH)D levels⁴⁴ most strongly associated CYP2R1 variant with 25(OH)D levels
Batai et al. 2014, Human Genetics — rs1993116 showed the strongest CYP2R1 signal in European Americans, while rs12794714 was the leading variant in African Americans, demonstrating that the causal architecture differs by ancestry.

The Evidence

The clearest functional evidence comes from a 2019 Japanese study⁵⁵ 2019 Japanese study
Arai T et al. Association of vitamin D levels and vitamin D-related gene polymorphisms with liver fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease. Dig Liver Dis, 2019 of 229 NAFLD patients in which non-AA genotype at rs1993116 emerged as an independent predictor of vitamin D deficiency (≤20 ng/mL) in multivariate analysis — meaning the association held even after controlling for sun exposure, BMI, season, and other confounders.

A 2018 Egyptian study⁶⁶ 2018 Egyptian study
Sedky NK et al. Genetic Variants of CYP2R1 Are Key Regulators of Serum Vitamin D Levels and Incidence of Myocardial Infarction in Middle-Aged Egyptians. Curr Pharm Biotechnol, 2018 in 323 subjects found that AG/GG genotypes at rs1993116 defined the high-risk grouping for lower serum 25(OH)D and elevated myocardial infarction risk (combined OR 14.1 for all three high-risk CYP2R1 genotypes together).

In a Chinese rural population, Wang et al. (2018)⁷⁷ Wang et al. (2018)
Wang Y et al. Triangular relationship between CYP2R1 gene polymorphism, serum 25(OH)D3 levels and T2DM in a Chinese rural population. Gene, 2018 found that the non-AA genotype carried 64% higher odds of type 2 diabetes (OR 1.64, 95% CI 1.09–2.46, P=0.048) in 794 subjects, consistent with the established link between vitamin D insufficiency and insulin resistance.

Robien et al. (2013)⁸⁸ Robien et al. (2013)
Robien K et al. Genetic and environmental predictors of serum 25-hydroxyvitamin D concentrations among middle-aged and elderly Chinese in Singapore. Br J Nutr, 2013 replicated the association in 504 Chinese Singaporeans, confirming that rs1993116 and rs10741657 both contribute independently to circulating 25(OH)D levels across diverse populations.

A 2013 analysis of 5,604 hepatitis C patients found that genotypes associated with reduced 25(OH)D via CYP2R1 variants trended toward higher hepatocellular carcinoma risk (OR 1.13, P=0.07)⁹⁹ (OR 1.13, P=0.07)
Lange CM et al. Genetic analyses reveal a role for vitamin D insufficiency in HCV-associated hepatocellular carcinoma development. PLoS One, 2013, further illustrating the downstream consequences of genetically lower vitamin D.

Practical Actions

The core intervention is the same regardless of which CYP2R1 variant is limiting your 25(OH)D production: increase the substrate (vitamin D3 input) to compensate for slower conversion. G allele carriers typically need higher supplementation doses than the general population to achieve the same circulating 25(OH)D level. Testing serum 25(OH)D is the only reliable way to calibrate the right dose — an optimal level is generally considered 40–60 ng/mL (100–150 nmol/L).

Magnesium is a cofactor for both CYP2R1 and the downstream CYP27B1 hydroxylase; deficiency impairs vitamin D conversion independently of genotype, so GG carriers have extra reason to ensure adequate magnesium intake.

Interactions

rs1993116 interacts with rs10741657, the other major CYP2R1 locus. Both variants influence CYP2R1 expression and are partially correlated; carriers of risk alleles at both loci have compounded 25-hydroxylation impairment.

Beyond CYP2R1, the vitamin D pathway involves several other gene variants already profiled: rs12785878 (DHCR7/NADSYN1, skin synthesis), rs4588 and rs7041 (GC/VDBP, transport), rs2228570 (VDR FokI, receptor sensitivity), and rs6013897 (CYP24A1, degradation). Individuals carrying risk alleles across two or more of these loci face compounded insufficiency risk; large GWAS data showed 2.47-fold increased odds of vitamin D insufficiency for the highest multi-locus risk score.

Every normal heartbeat ends the same way: a wave of potassium ions flows out through millions of hERG channels, repolarizing ventricular muscle and resetting the electrical system for the next beat. The hERG channel¹¹ hERG channel
encoded by KCNH2, the human ether-à-go-go related gene; it carries the rapid delayed rectifier current IKr, the dominant current driving the final phase of cardiac repolarization is so critical to this process that loss-of-function mutations anywhere in its 1,159-amino-acid sequence can prolong the QT interval and trigger life-threatening ventricular arrhythmias. rs199473521 substitutes asparagine (uncharged, polar) for the normal lysine (positively charged) at position 595 — a residue in the C-linker domain that connects the channel's last transmembrane helix to its regulatory intracellular domain.

The Mechanism

Position 595 sits in the C-linker of Kv11.1/hERG, the eight-residue segment that couples the S6 transmembrane helix to the cyclic nucleotide binding homology domain (CNBHD)²² cyclic nucleotide binding homology domain (CNBHD)
a regulatory domain that modulates channel opening and closing; mutations anywhere in the C-linker alter the allosteric coupling between the gate and this regulatory module. The lysine at position 595 contributes to the electrostatic environment of this linker. Replacing it with asparagine (K595N) removes a positive charge, disrupts the local conformation, and is predicted by multiple paralogous-annotation frameworks to destabilize channel gating and reduce IKr. The net effect is loss-of-function: fewer functional hERG channels deliver less outward potassium current during the plateau of the action potential, delaying repolarization and lengthening the QT interval on the surface ECG.

Critically, K595 is conserved across species and across the broader voltage-gated potassium channel superfamily. Ware et al.³³ Ware et al.
Paralogous annotation of disease-causing variants in long QT syndrome genes. Human Mutation, 2012 developed a method that correctly classified 98.4% of known pathogenic KCNH2 variants by comparing residue conservation across paralogues — a framework that flags K595N as high-priority among likely disease-causing changes.

The Evidence

rs199473521 was submitted to ClinVar (VCV000067273, RCV000057989) by the Cardiovascular Biomedical Research Unit at Royal Brompton & Harefield NHS Foundation Trust as a literature-report entry for congenital long QT syndrome, citing the Shimizu et al. 2009 and Ware et al. 2012 publications. It carries no ClinVar star rating — the single submitter recorded it as "not provided" with no independent functional validation on record. This places it in a common clinical grey zone: an ultra-rare KCNH2 missense variant (absent from gnomAD across all populations) at a conserved charged position, in a family or patient context consistent with LQT2, but without peer-reviewed electrophysiological characterization of the K595N substitution specifically.

The clinical genetics framework for interpreting ultra-rare KCNH2 missense variants is well established. Kapa et al.⁴⁴ Kapa et al.
Genetic testing for long-QT syndrome: distinguishing pathogenic mutations from benign variants. Circulation, 2009 showed that among 388 definite LQT2 patients, missense variants in the C-linker and transmembrane domains had near-100% estimated pathogenicity. Shimizu et al.⁵⁵ Shimizu et al.
Genotype-phenotype aspects of type 2 long QT syndrome. JACC, 2009 documented in 858 LQT2 patients that beta-blockers reduced the risk of first cardiac events by 63% (p < 0.001), establishing the therapeutic approach that would apply to K595N carriers regardless of whether functional data are ever published.

LQT2 has a characteristic trigger profile: auditory stimuli (alarm clocks, doorbells, telephone rings) and emotional startle provoke the bulk of arrhythmic events, and events are more common during rest, sleep, or emotion than during exercise — the reverse of LQT1. Women with LQT2 experience higher event rates than men, particularly around hormonal transitions (postpartum, perimenopause).

Practical Actions

Carriers of the K595N variant should be evaluated promptly by a cardiac electrophysiologist. The primary intervention for LQT2 is beta-blocker therapy (nadolol or propranolol at weight-adjusted doses), which is protective across the LQT2 spectrum. Auditory-trigger minimization — silencing or vibrating phones and alarms at night — is a specific, genotype-appropriate lifestyle change. Maintaining potassium and magnesium in the upper-normal range is critical because both electrolytes directly support IKr function; hypokalemia can precipitate torsades de pointes even without drug provocation in LQT2 carriers. Any drug that prolongs the QT interval is contraindicated — the CredibleMeds list (crediblemeds.org) is the maintained reference.

For high-risk carriers (prior syncope, prior cardiac arrest, QTc > 500 ms), an implantable cardioverter-defibrillator (ICD) may be indicated alongside pharmacotherapy. First-degree relatives should undergo cascade ECG screening and genetic testing.

Interactions

K595N may interact with the common KCNH2 modifier rs1805123 (K897T): homozygous K897T individuals have a baseline IKr reduction and may experience amplified QT prolongation if they co-inherit a loss-of-function variant like K595N. This interaction follows the general LQT2 modifier framework documented by Nof et al. 2010 (PMID 20181576) in which K897T GG homozygosity on a pathogenic KCNH2 background produces substantially greater IKr loss. Compound carriers of K595N and NOS1AP rs10918594 G alleles (PMID 19822806) may face additional QT prolongation through independent electrophysiological mechanisms.

Most people think of tooth enamel as something that forms passively in the womb and during early childhood. What is less well known is that forming enamel passes through two fundamentally different phases — and the second phase, maturation, is where the bulk of mineral is deposited and where enamel either becomes hard or stays soft. The gene KLK4, encoding kallikrein-related peptidase 4¹¹ kallikrein-related peptidase 4
a serine protease secreted by transition and maturation-stage ameloblasts that aggressively degrades residual enamel matrix proteins to clear space for mineral expansion, controls this finishing step. rs2235091 is an intronic variant in KLK4 that has been linked to caries susceptibility and molar hypomineralization in multiple populations.

During the secretory stage of enamel formation, ameloblasts lay down a protein-rich organic matrix — predominantly amelogenin — that templates the growth of long, thin hydroxyapatite crystals. At the start of maturation, this matrix must be almost entirely removed so that the crystals can thicken, coalesce with adjacent crystals, and reach the high mineral density (~96% by weight) that gives mature enamel its extraordinary hardness. KLK4 is the enzyme primarily responsible for this protein clearance: it is secreted at high levels by maturation-stage ameloblasts and cleaves amelogenin and other enamel proteins at numerous sites, enabling their endocytic removal.

[Klk4 knockout mice | Hu et al., 2008, PubMed 19132006] develop enamel that retains a large amount of residual organic matrix: the crystals fail to fully expand, the enamel remains hypomineralized and pigmented (from retained matrix proteins), and it chips and abrades readily. In humans, homozygous loss-of-function mutations in KLK4 (e.g., the W153X nonsense mutation identified by Hart et al., 2004) cause autosomal recessive pigmented hypomaturation amelogenesis imperfecta — enamel of normal thickness that is radiographically soft and clinically fragile.

rs2235091 is an intronic variant whose precise molecular effect has not been characterized. Intronic variants can influence pre-mRNA splicing, alter intronic enhancer sequences, or affect RNA secondary structure and stability. Because KLK4 expression is tightly regulated in a narrow developmental window (transition and early maturation stage), even subtle reductions in protease expression or activity could impair matrix clearance and leave enamel marginally less mineralized than average — not dramatically enough to cause amelogenesis imperfecta, but enough to shift the threshold for acid-mediated demineralization.

The most comprehensive evidence comes from the Czech ELSPAC cohort Broukal et al., Clin Oral Investig, 2022²² Broukal et al., Clin Oral Investig, 2022
Polymorphisms in genes expressed during amelogenesis and their association with dental caries: a case-control study, which analysed 611 children with permanent dentition. In that cohort, the A allele of rs2235091 was significantly more common among caries-affected children than caries-free controls (any caries: OR 1.37, 95% CI 1.05–1.80, p=0.014; severe caries DMFT ≥ 6: OR 1.76, 95% CI 1.20–2.58, p=0.002). The AA genotype reached an OR of 4.15 (95% CI 1.54–11.23, p=0.006) compared to GG homozygotes. Haplotype analysis incorporating four KLK4 SNPs showed the GAGA haplotype (containing the rs2235091 A allele) strongly pro-carious (p=0.001 for DMFT > 0; p < 0.001 for DMFT ≥ 6), while the GAGG haplotype (protective G at rs2235091) was protective (p=0.003). Notably, no significant effect was detected in primary dentition (150 children), suggesting the association is specific to permanent enamel maturation.

The Iowa Fluoride Study³³ Iowa Fluoride Study
Wang et al., 2012; family-based association test in 333 Caucasian parent-child trios found the G allele protective against caries across pit/fissure surfaces (p=0.004) and smooth surfaces (p=0.02), consistent with the Czech findings on direction of effect. A Polish case-control study of 96 children (aged 20–42 months) identified rs2235091 as one of five SNPs significantly associated with caries incidence (p=0.0085). Most recently, a Brazilian preliminary study (118 children) found that the A allele of rs2235091 was associated with molar hypomineralization (MH) with an OR of 3.75 (95% CI 1.65–7.81, p=0.001), with the association amplified when combined with childhood antibiotic exposure — pointing toward a gene-environment interaction in the maturation window.

The overall picture is moderate evidence: three independent populations show the A allele conferring risk or the G allele conferring protection, with effect sizes in the range of OR 1.4–1.8 for any caries and up to OR 4.15 for the AA genotype in severe caries. The variant does not appear in ClinVar as clinically significant, and no functional characterization of its molecular effect is yet published. The evidence is primarily observational in pediatric European and Brazilian populations.

Because rs2235091 is intronic and its functional effect is not yet established, we cannot prescribe a specific molecular intervention. The actionable implication is that carriers of the A allele — particularly AA homozygotes — have a modestly elevated baseline risk for caries in permanent dentition and molar hypomineralization. This shifts the cost-benefit calculus for preventive dentistry in favor of more intensive protocols: higher-strength fluoride, remineralizing agents, and increased check-up frequency are the evidence-backed tools for people with genetically suboptimal enamel maturation.

Calcium and phosphate adequacy during the enamel maturation window (roughly birth to age 12) is an important cofactor — even normal KLK4-mediated protein clearance requires sufficient mineral substrate to fill the cleared space. The combination of reduced KLK4 efficiency and low dietary calcium/phosphate during childhood is likely worse than either alone.

rs2235091 has been studied as part of KLK4 haplotype blocks alongside rs198968, rs2242670, and rs2978642. The GAGA haplotype incorporating all four SNPs shows stronger association than any single SNP, supporting a polygenic model within the KLK4 locus. Additionally, AMELX rs17878486 and KLK4 rs2235091 appear to act as part of a broader enamel-gene cluster (also including MMP20 and MMP13) with joint association with caries risk (p < 10⁻⁵ in gene-cluster analyses). The AMELX–KLK4 interaction is biologically coherent: AMELX shapes the secretory matrix, and KLK4 clears it — defects in either step can impair final enamel quality. A compound action for AA+TT (rs2235091 AA + rs17878486 TT) is a reasonable candidate for future research once both variants are fully characterized.

Hidden in an intron of the KCNK5 gene is a common variant that nudges the brain slightly closer to migraine. KCNK5 encodes TASK2¹¹ TASK2
TWIK-related acid-sensitive K+ channel 2 — a two-pore-domain background potassium channel that generates a steady hyperpolarising current to keep neurons just below the firing threshold. Unlike voltage-gated potassium channels that open and close in milliseconds, TASK2 operates as a constitutive "leak" channel — always slightly open, always gently pulling the membrane voltage away from the danger zone. When TASK2 expression falls, that brake weakens.

The Mechanism

rs10456100 sits within an intron of KCNK5 on chromosome 6 (GRCh38 position 39,215,694). The T risk allele acts as an expression quantitative trait locus (eQTL): carriers show significantly lower KCNK5 mRNA levels in subcutaneous adipose tissue (P = 2.70×10⁻¹⁰), and the same directional effect has been observed in brain-relevant tissues. Lower TASK2 expression reduces the background K+ conductance that normally holds neuronal membrane potential in check, meaning neurons are fractionally closer to their depolarisation threshold at rest.

This matters for migraine because cortical spreading depression (CSD)²² cortical spreading depression (CSD)
the slow wave of near-complete depolarisation that sweeps across the cortex and is thought to underlie migraine aura — and to trigger the trigeminovascular pain cascade even in migraine without aura is exquisitely sensitive to background K+ homeostasis. When extracellular K+ rises above ~10 mM — partly due to reduced TASK2-mediated K+ efflux — it can ignite and sustain CSD propagation. KCNK5 also shows strong expression in hippocampal pyramidal neurons and cerebellar granule and Purkinje cells³³ hippocampal pyramidal neurons and cerebellar granule and Purkinje cells, regions where metabolic and ionic shifts during CSD are well-documented.

TASK2 is additionally pH-gated: it activates under alkaline conditions and inhibits under acidic ones. The metabolic acidosis accompanying CSD would suppress TASK2 activity, reducing the K+ recycling that normally terminates the depolarisation wave. T-allele carriers begin with less TASK2 expression to start with, so this failsafe mechanism is further attenuated.

The Evidence

The largest genetic evidence comes from Hautakangas et al. 2022⁴⁴ Hautakangas et al. 2022
Genome-wide analysis of 102,084 migraine cases identifies 123 risk loci. Nature Genetics, which identified rs10456100-T as one of 123 genome-wide significant migraine loci (OR = 1.052, P = 9.0×10⁻¹⁹). The T allele is common — about 28% of the global population carries at least one copy — and the per-allele effect is modest but robustly replicated.

Earlier GWAS meta-analyses confirmed this signal: Gormley et al. 2016⁵⁵ Gormley et al. 2016
Nature Genetics, with 59,674 cases, reported OR = 1.06 at P = 7×10⁻¹³ at this locus. The KCNK5 locus has now been replicated independently in European, Han Chinese, and Latin American cohorts, establishing it as one of the most consistently replicated non-CGRP migraine risk loci.

A Han Chinese study (Zhang et al. 2021, Scientific Reports)⁶⁶ (Zhang et al. 2021, Scientific Reports) confirmed the T allele association with migraine without aura in two independent Chinese samples (P = 9.0×10⁻⁹ in discovery, replicated), and demonstrated the adipose eQTL specifically, suggesting the intronic variant affects a regulatory element controlling KCNK5 transcription.

Practical Actions

For T allele carriers, the practical implication is a slightly lower migraine threshold — the threshold is not fixed, and several modifiable factors interact with neuronal excitability to shift it up or down. Magnesium stabilises NMDA receptors and reduces cortical hyperexcitability; riboflavin (vitamin B2) supports mitochondrial energy production, which is critical for maintaining ion gradients (including K+) across neuronal membranes. Both have specific evidence in migraine prevention and are more directly relevant for a K+-channel variant than generic anti-inflammatory approaches.

Sleep deprivation and irregular sleep are among the strongest environmental triggers of CSD-susceptibility, likely because K+ homeostasis during sleep differs substantially from wakefulness — the glymphatic system and K+ clearance mechanisms operate differently in NREM sleep, and abrupt disruptions elevate cortical excitability.

Interactions

KCNK5 belongs to the two-pore-domain K+ channel superfamily, which also includes KCNK18 (TRESK), a channel in which a rare frameshift mutation causes familial migraine with aura. The TRESK and TASK2 channels share complementary roles in regulating trigeminal neuron excitability — variants in both genes converge on the same threshold-setting mechanism. The GWAS catalog also notes a pleiotropic association between rs10456100-T and coronary artery disease risk (van der Harst 2017), potentially reflecting TASK2 expression in vascular or immune cells; the mechanistic basis for this pleiotropy is not yet established.